Information on EC 3.4.23.24 - Candidapepsin

69458-91-9

-

2-methoxy-2,4-diphenyl-3(2H)furanone + H2O

?

4-(4-dimethylaminophenylazo)benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-[5-(2-aminoethyl)-amino]naphthalene-1-sulfonic acid + H2O

4-(4-dimethylaminophenylazo)benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His + Thr-[5-(2-aminoethyl)-amino]naphthalene-1-sulfonic acid

Substrates: -
Products: -

?

4-(4-dimethylaminophenylazo)benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-[5-(2-aminoethyl)-amino]naphthalene-1-sulfonic acid + H2O

?

Substrates: -
Products: -

?

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys-Leu-Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid + H2O

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys + Leu-Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys-Leu-Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid + H2O

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys-Leu + Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid

4-(4-dimethylaminophenylazo)benzyl-Pro-Lys-Val-Glu-Leu-Thr-Gly-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid + H2O

4-(4-dimethylaminophenylazo)benzyl-Pro-Lys-Val-Glu + Leu-Thr-Gly-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid

Ala-Thr-His-Gln-Val-Tyr-4-nitrophenylalanine-Val-Arg-Lys-Ala + H2O

Ala-Thr-His-Gln-Val-Tyr + 4-nitrophenylalanine-Val-Arg-Lys-Ala

-

Substrates: -
Products: -

?

Albumin + H2O

?

Arg-Glu-[5-(aminoethyl)aminonaphthalene sulfonate]-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys-[4'-dimethylaminoazobenzene-4-carboxylate]-Arg + H2O

?

azocasein + H2O

?

-

Substrates: -
Products: -

?

Azocoll + H2O

?

-

Substrates: -
Products: -

?

Bovine serum albumin + H2O

?

8 entries

Bovine serum albumin + H2O

Hydrolyzed bovine serum albumin

casein + H2O

?

8 entries

Collagen + H2O

?

complement component 3b + H2O

?

Substrates: substrate for isoforms Sapp1p and Sapp2p
Products: -

?

complement component 4b + H2O

?

Substrates: substrate for isoforms Sapp1p and Sapp2p
Products: -

?

complement component C3b + H2O

?

-

Substrates: -
Products: -

?

complement component C4b + H2O

?

-

Substrates: -
Products: -

?

complement component C5 + H2O

?

-

Substrates: -
Products: -

?

complement components C3b + H2O

?

-

Substrates: substrate for isoforms Sap1, Sap2, Sap3, but not for Sap9
Products: -

?

complement components C4b + H2O

?

-

Substrates: substrate for isoforms Sap1, Sap2, Sap3, but not for Sap9
Products: -

?

complement components C5 + H2O

?

-

Substrates: substrate for isoforms Sap1, Sap2, Sap3, but not for Sap9
Products: -

?

Dabcyl-EHVKLVE-EDANS + H2O

?

-

718369

Substrates: -
Products: -

?

dabcyl-Glu-His-Val-Lys-Leu-Val-Glu-EDANS

dabcyl-Glu-His-Val-Lys-COOH + Leu-Val-Glu-EDANS

dabcyl-Glu-His-Val-Lys-Leu-Val-Glu-EDANS + H2O

dabcyl-Glu-His-Val-Lys-Leu + Val-Glu-EDANS

dabcyl-Pro-Lys-Val-Glu-Leu-Thr-Gly-Glu-EDANS

dabcyl-Pro-Lys-Val-Glu-COOH + Leu-Thr-Gly-Glu-EDANS

E-cadherin + H2O

?

-

709656

Substrates: Candida albicans strains JKC19 and SC5314 degrade E-cadherin at pH 4.0, the 10fold concentrated growth media of the strains HLC-52, HLC-54, 32723 and B1134 cause degradation at pH 4.0, strains HLC-52 and HLC-54 also at pH 6.0
Products: -

?

ELSKRSSPS + H2O

ELSK + L-Arg + SSPS

Substrates: 98% conversion
Products: -

?

factor H + H2O

?

factor H-related protein 5 + H2O

?

Substrates: substrate for isoform Sapp2p
Products: -

?

fluorescein-labeled casein + H2O

?

FRETS-25Ala + H2O

?

Substrates: isozyme Sap1 shows highest activity towards FRETS-25Ala
Products: -

?

FRETS-25Xaa + H2O

?

Substrates: all Sap isozymes prefer Arg and Lys at the Xaa position
Products: -

?

Hemoglobin + H2O

?

hide powder azure + H2O

?

-

Substrates: -
Products: -

?

Human stratum corneum + H2O

?

-

30695

Substrates: -
Products: -

?

Keratin + H2O

?

L-Arg-7-amido-4-methylcoumarin + H2O

L-Arg + 7-amino-4-methylcoumarin

LPVNATSE + H2O

LPVN + ATSE

Substrates: 28% conversion
Products: -

?

LTEKRDSIS + H2O

LTEKR + L-Asp + Ser-Ile-Ser

Substrates: 100% conversion
Products: -

?

Lys-Pro-Ala-Arg-Phe-Nph-Arg-Leu + H2O

?

Substrates: -
Products: -

?

Lys-Pro-Ala-Arg-Phe-Nph-Arg-Leu + H2O

Lys-Pro-Ala-Arg-Phe + Nph-Arg-Leu

Substrates: -
Products: -

?

Lys-Pro-Ala-Glu-Phe-4-nitrophenylalanine-Ala-Leu + H2O

Lys-Pro-Ala-Glu-Phe + 4-nitrophenylalanine-Ala-Leu

-

Substrates: -
Products: -

?

Lys-Pro-Leu-Glu-Met-4-nitrophenylalanine-Ala-Leu + H2O

Lys-Pro-Leu-Glu-Met + 4-nitrophenylalanine-Ala-Leu

-

Substrates: -
Products: -

?

macrophage factor H-receptor CR3 + H2O

?

-

Substrates: the enzyme cleaves and inactivates macrophage factor H-receptor CR3
Products: -

?

macrophage factor H-receptor CR4 + H2O

?

-

Substrates: the enzyme cleaves and inactivates macrophage factor H-receptor CR4
Products: -

?

Myeloma proteins of the type A1 and A2 + H2O

?

oxidized insulin B chain + H2O

?

Substrates: cleavage sites of Sap2p: FV-/-NQHLCGSHL-/-V-/-EA-/-LYLVCGERGFF-/-YTPKA
Products: -

?

Oxidized insulin B-chain + H2O

?

-

Substrates: low side-chain specificity, preferential attack on hydrophobic amino acid residues
Products: -

?

PMVELAGE + H2O

PMVE + L-Leu + AGE

Substrates: cleavage of Sapp2p, 81% conversion
Products: -

?

PMVELAGE + H2O

PMVEL + AGE

Substrates: cleavage of Sapp1p, 100% conversion
Products: -

?

PMVELGGE + H2O

PMVEL + GGE

Substrates: 100% conversion
Products: -

?

PMVELHGE + H2O

PMVEL + HGE

Substrates: 100% conversion
Products: -

?

PMVELPGE + H2O

PMVEL + PGE

Substrates: 100% conversion
Products: -

?

PMVELQGE + H2O

PMVE + L-Leu + QGE

PMVELQGE + H2O

PMVEL + QGE

PMVELTGE + 2 H2O

PMVE + L-Leu + TGE

PMVELTGE + H2O

PMVEL + TGE

PMVELWGE + H2O

PMVE + L-Leu + WGE

Substrates: cleavage of Sapp2p, 40% conversion
Products: -

?

PMVELWGE + H2O

PMVEL + WGE

Substrates: cleavage of Sapp1p, 76% conversion
Products: -

?

PMVEMWGE + H2O

PMVEM + WGE

Substrates: 100% conversion
Products: -

?

PMVMLWGE + H2O

PMVML + WGE

protein + H2O

hydrolyzed protein

Proteinase inhibitors of human serum + H2O

?

-

Substrates: -
Products: -

?

additional information

?

-

73 entries

Bovine serum albumin + H2O

?

-

753800

Substrates: -
Products: -

?

casein + H2O

?

complement component 3b + H2O

?

Substrates: substrate for isoforms Sapp1p and Sapp2p
Products: -

?

complement component 4b + H2O

?

Substrates: substrate for isoforms Sapp1p and Sapp2p
Products: -

?

complement component C3b + H2O

?

-

Substrates: -
Products: -

?

complement component C4b + H2O

?

-

Substrates: -
Products: -

?

complement component C5 + H2O

?

-

Substrates: -
Products: -

?

factor H + H2O

?

factor H-related protein 5 + H2O

?

Substrates: substrate for isoform Sapp2p
Products: -

?

macrophage factor H-receptor CR3 + H2O

?

-

Substrates: the enzyme cleaves and inactivates macrophage factor H-receptor CR3
Products: -

?

macrophage factor H-receptor CR4 + H2O

?

-

Substrates: the enzyme cleaves and inactivates macrophage factor H-receptor CR4
Products: -

?

protein + H2O

hydrolyzed protein

additional information

?

-

50 entries

(1R,5R,7R)-3-benzyl-7-(piperidin-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

74% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-(2-hydroxyethyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

71% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-(3-hydroxypropyl)-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

23% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

31% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-[(2R)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

29% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

30% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

71% inhibition at 0.02 mM

(1R,5R,7R)-3-benzyl-N-[(2S)-1-hydroxypropan-2-yl]-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

35% inhibition at 0.02 mM

(1R,5R,7R)-N-(2-aminoethyl)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxamide

-

63% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-(1,4-diazepan-1-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

63% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-(morpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

62% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-(thiomorpholin-4-ylcarbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

58% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-[[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

34% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-[[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

48% inhibition at 0.02 mM

(1R,5S,7R)-3-benzyl-7-[[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl]-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

58% inhibition at 0.02 mM

(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide

-

60% inhibition at 0.02 mM

(1R,5S,7S)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(S)-methylbutyl]amide

-

33% inhibition at 0.02 mM

(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid benzyl-(1-hydroxymethyl-3-methylbutyl)amide

-

35% inhibition at 0.02 mM

(1S,5R,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid [1-hydroxymethyl-3(R)-methylbutyl]amide

-

29% inhibition at 0.02 mM

(1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

-

50% inhibition at 0.02 mM

(2R,3S)-phenylnorstatine

(2S,3S)-phenylnorstatine

(3S,4S)-phenylstatine

(3S,4S)-statine

1,2-epoxy-3-(4-nitrophenoxy)propane

2-cymene

-

3-cymene

-

4-cymene

-

acetyl-Phe-Ile-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl

-

transition-state peptidomimetic TS-41

acetyl-Trp-Phe-psi[OH-OH]-Phe-Trp-acetyl

-

transition-state peptidomimetic TS-49

acetyl-Trp-Ser-Phe-psi[OH-OH]-Phe-kynurenic acid

-

transition-state peptidomimetic TS-57

acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl

-

transition-state peptidomimetic TS-43

acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-acetyl

-

transition-state peptidomimetic TS-75

acetyl-Trp-Val-Phe-psi[OH-OH]-Phe-Val-Trp-acetyl

-

transition-state peptidomimetic TS-42

amprenavir

-

most effective inhibitor of Sap2, about 92% inhibition at 0.1 mM

708525

antipain

-

partial

Aprotinin

-

Arg-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg

-

transition-state peptidomimetic TS-2

benzyloxycarbonyl-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

-

benzyloxycarbonyl-L-Val-L-Val-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

-

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-( (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

-

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

-

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-NH2

-

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OH

-

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-OMe

-

benzyloxycarbonyl-L-Val-L-Val-statine-L-Ala-statine-OH

-

BocValValPstAla(3R,4R)PstOMe

-

-

BocValValPstAlaOMe

-

-

BocValValPstAlaPstNH2

-

-

BocValValPstAlaPstO

-

-

Butanedione

-

cedrane

-

chymostatin

-

cineole

-

davanol

-

Diazoacetylnorleucine methyl ester

dillapiole

-

ethyl 4-[[(1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]oct-7-yl]carbonyl]piperazine-1-carboxylate

-

74% inhibition at 0.02 mM

fluconazole

-

foeniculin

-

indinavir

-

inhibitor A-70450

-

isovaleryl-Val-Val-statyl-Ala-statyl-OH

-

kynurenic acid-Dtg-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid

-

transition-state peptidomimetic TS-92

kynurenic acid-Dtg-Phe-psi[OH-OH]-Phe-phenoxyacetic acid

-

transition-state peptidomimetic TS-63

kynurenic acid-Thr-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid

-

transition-state peptidomimetic TS-93

kynurenic acid-Thr-Phe-psi[OH-OH]-Phe-kynurenic acid

-

transition-state peptidomimetic TS-59

kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-dimethylphenoxyacetic acid

-

transition-state peptidomimetic TS-94

kynurenic acid-Val-Phe-psi(S,R,S)[OH]-Phe-Val-kynurenic acid

-

transition-state peptidomimetic TS-91

kynurenic acid-Val-Phe-psi[OH-OH]-Phe-Val-kynurenic acid

-

best inhibitor; transition-state peptidomimetic TS-70

ligustilide

-

lopinavir

-

Lys-Ile-Phe-psi[CH2-NH]-Phe-Gln-Arg

-

transition-state peptidomimetic TS-23

methyl palmitate

-

mycogenic silver nanoparticles

5 entries

-

nelfinavir

-

pepstatin

pepstatin A

phellandrene

-

phenylmethylsulfonyl fluoride

-

ritonavir

saquinavir

SDS

-

tolerated at 0.01% w/v, decrease of activity at 0.1% w/v, 1% completely destroys activity within a few min

squinavir

-

t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Dtg-phenoxyacetic acid

-

transition-state peptidomimetic TS-54

t-butoxylcarbonyl-Phe-psi[OH-OH]-Phe-Glu-Phe-acetyl

-

transition-state peptidomimetic TS-53

tert-butoxycarbonyl-Val-Val-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-Ala-phenylstatyl-O-methyl ester

-

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-OH

-

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-O-methyl ester

-

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-NH2

-

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-O-methyl ester

-

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-OH

-

Tetradecanal

-

thujanol

-

Thymol

-

totarol

-

Trp-Ile-Phe-psi[CH2-NH]-Phe-Gln-Trp

-

transition-state peptidomimetic TS-10

Xan-Dtg-Val-psi(S,R,S)[OH]-Val-Dtg-Xan

-

transition-state peptidomimetic TS-90

additional information

16 entries

-

fluconazole

nonionic detergents

-

Triton X-100, Tween-80, Nonidet P-40, slight improvement of activity

-

4.3

4-(4-dimethylaminophenylazo)benzoyl-gamma-aminobutyryl-Ile-HIs-Pro-Phe-His-Leu-Val-Ile-His-Thr-[5-(2-aminoethyl)-amino]naphthalene-1-sulfonic acid

isoenzyme Sap2p

0.00113 - 0.0028

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys-Leu-Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid

0.0122

Ala-Thr-His-Gln-Val-Tyr-4-nitrophenylalanine-Val-Arg-Lys-Ala

-

0.07

albumin

-

-

0.008

Lys-Pro-Ala-Arg-Phe-Nph-Arg-Leu

pH 3.25, isoenzyme Sap2p

0.0092

Lys-Pro-Ala-Glu-Phe-4-nitrophenylalanine-Ala-Leu

-

0.0129

Lys-Pro-Leu-Glu-Met-4-nitrophenylalanine-Ala-Leu

-

15.2 - 48.7

4-(4-dimethylaminophenylazo)benzyl-Glu-His-Val-Lys-Leu-Val-Glu-5-(2-aminoethylamino)-1-naphthalenesulfonic acid

1.41

Ala-Thr-His-Gln-Val-Tyr-4-nitrophenylalanine-Val-Arg-Lys-Ala

-

31.8

Lys-Pro-Ala-Glu-Phe-4-nitrophenylalanine-Ala-Leu

-

24.11

Lys-Pro-Leu-Glu-Met-4-nitrophenylalanine-Ala-Leu

-

0.0000143 - 0.000044

benzyloxycarbonyl-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

0.000174 - 0.002782

benzyloxycarbonyl-L-Val-L-Val-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

0.0000002 - 0.0000003

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-( (3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

0.0000001 - 0.0000004

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3R,4R)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OMe

0.0000001

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-NH2

0.0000018 - 0.0000066

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-OH

0.0000072 - 0.0000146

benzyloxycarbonyl-L-Val-L-Val-((3S,4S)-4-amino-3-hydroxy-5-phenylpentanoic acid)-L-Ala-OMe

0.00000003 - 0.0000003

benzyloxycarbonyl-L-Val-L-Val-statine-L-Ala-statine-OH

0.0000004

BocValValPstAla(3R,4R)PstOMe

pH not specified in the publication, temperature not specified in the publication

-

0.0000146

BocValValPstAlaOMe

pH not specified in the publication, temperature not specified in the publication

-

0.0000001

BocValValPstAlaPstNH2

pH not specified in the publication, temperature not specified in the publication

-

0.0000066

BocValValPstAlaPstO

pH not specified in the publication, temperature not specified in the publication

-

0.0000003

isovaleryl-Val-Val-statyl-Ala-statyl-OH

-

0.0000003 - 0.017

pepstatin A

0.0003 - 0.0019

ritonavir

0.0169 - 0.32

saquinavir

0.0068

squinavir

-

0.005301

tert-butoxycarbonyl-Val-Val-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-Ala-phenylstatyl-O-methyl ester

-

0.0000009

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-(3R,4R)-4-amino-3-hydroxy-5-phenylpentanoyl-OH

-

0.0000065

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-O-methyl ester

-

0.00000254

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-NH2

-

0.0000004

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-O-methyl ester

-

0.0000066

tert-butoxycarbonyl-Val-Val-phenylstatyl-Ala-phenylstatyl-OH

-

additional information

-

0.02

(1S,5S,7S)-3-benzyl-7-(piperidine-1-carbonyl)-6,8-dioxa-3-azabicyclo[3.2.1]octan-2-one

Candida albicans

-

in 50 mM sodium citrate, pH 3.2, at 37°C

0.000027

pepstatin A

Candida albicans

IC50 for sap2p: 27 nM

additional information

2.5

isozyme Sap8

2.5 - 3.5

-

2.5 - 3.9

-

hemoglobin

3

isozyme Sap3

3.2

-

3.3

Candida olea

-

denatured hemoglobin

3.5

-

3.7

-

bovine serum albumin

4

4 - 5.5

-

chaotropic agents such as KSCN shift the pH optimum to 6.5

4.5

isoenzyme Sap2p, hydrolysis of 4-(4-dimethylaminophenylazo)benzoyl-gamma-aminobutyryl-Ile-HIs-Pro-Phe-His-Leu-Val-Ile-His-Thr-[5-(2-aminoethyl)-amino]naphthalene-1-sulfonic acid

5

5.5

isozyme Sap9

6

isozyme Sap10

6.5

isozyme Sap7

2.5 - 6

-

inactive below and above

30695

42

Candida olea

-

denatured hemoglobin

45

-

at pH 3.0

0 - 42

Candida olea

-

0°C: 5-10% of activity maximum, 42°C: activity maximum

6.1

Q6FTZ7

calculated from amino acid sequence

752651

7.6

Candida albicans ATCC 20955

isoelectric focusing

-

-

-

Candida albicans CBS 5982

-

Candida albicans CAI4

-

753796

Q5AC08

SwissProt

-

700343

-

Candida albicans CBS-2730

-

-

Candida albicans H12

-

-

Candida albicans SG5314

-

SwissProt

Candida olea

148

-

Candida olea 148

148

-

Candida parapsilosis CDC-317

13 entries

-

752386

G8B6Y8

UniProt

Candida parapsilosis CP386/IDE98

strain CP386/IDE98 isolated from human ear and CP924/IDE03 isolated from human urine

679921

P32950

UniProt

Candida parapsilosis P-69

Candida tropicalis

Candida tropicalis ATCC 750

-

754491

-

Clavispora lusitaniae

-

709816

-

Kluyveromyces marxianus

-

709816

-

KSY 188-5

Metschnikowia pulcherrima KSY 188-5

-

KSY 188-5

Meyerozyma guilliermondii

-

-

709816

-

culture condition:bovine serum albumin-grown cell

5 entries

Nakaseomyces glabratus BG2

-

754172

-

Nakaseomyces glabratus T-1639

-

UniProt

-

-

-

biofilms of Candida albicans secrete more SAPs than the planktonic form

-

culture condition:glucose-grown cell

P43094, P0DJ06, P0CY27, P0CY29, Q5A8N2, Q59VH7, Q5AEM6, Q59SU1

-

677597

-

-

30686, 30687, 30688, 30689

-

biofilms of Candida albicans secrete more SAPs than the planktonic form

-

-

additional information

Highest Expressing Human Cell Lines

Filter by:

Cell Line Links

Gene Links

malfunction

physiological function

11000

1 * 44000 + 1 * 11000, isozyme Sap9, SDS-PAGE

15000

1 * 52000 + 1 * 15000, isozyme Sap7, SDS-PAGE

29500

Candida olea

-

1 * 29500, Candida olea, SDS-PAGE

30900

Candida olea

-

Candida olea, gel filtration

35000

isozyme Sap8, calculated from amino acid sequence

35500

-

x * 35500, recombhinant truncated Sap2 protein, SDS-PAGE

36000

6 entries

36500

-

1 * 36500, Candida pulcherrima, SDS-PAGE

37000

38000

39000

40000

41000

42000

43000

44000

45000

47000

isozyme Sap7, calculated from amino acid sequence

52000

53000

isozyme Sap9, calculated from amino acid sequence

55000 - 60000

-

Candida albicans, proteinase A, gel filtration

86000

-

Candida albicans

30694

additional information

?

heterodimer

monomer

tetramer

glycoprotein

proteolytic modification

-

the Sapp1 precursor can be processed autocatalytically and by a membrane-bound processing proteinase. The pro-segment is indispensable for Sapp1p to attain an appropriate structure

complexed with inhibitor A-70450

of inhibited enzyme

-

Sap2p-inhibitor complex solved to 2.1 A

Sap3 with PepA in the presence of 10 mM zinc acetate, Sap3 without PepA in the presence of 0.2M potassium bromide, 15% PEG4000 and 0.1 M cacodylic acid/NaOH, pH 6.5. The Sap3 protein crystallizes in the trigonal space group P3(2)21 containing one molecule per asymmetric unit.

P0CY29

682748

in complex with pepstatin A, hanging drop vapor diffusion method, using 0.1 M MES pH 6.5, 30% (w/v) PEG 400

G8B6Y8

752386

Sapp1p in complex with pepstatin A, hanging drop vapor diffusion method, using 0.1 M Tris-HCl, pH 7.0, 2.0 M ammonium sulfate and 10% (v/v) glycerol, at 19°C

-

709715

structures of Sapp1p complexed to four peptidomimetic inhibitors

3 - 5

-

37°C, 12 h, maximal stability

6

-

unstable above

30694

6.5

-

extremely unstable above

8

Candida olea

-

10 min, over 70% loss of activity

8.4

-

above, alkaline denaturation accompanied by dimerization

9

Candida olea

-

10 min, complete loss of activity

30

Candida olea

-

pH 3.2, 60 min, slight loss of activity

37

-

10 min, 85% loss of activity at pH 7.5, 5% loss of activity at pH 6.6 and 7.0

45

46

Candida olea

-

inactivation above

50

-

stable at

30695

60

Candida olea

-

almost 80% loss of activity after 10 min, complete loss of activity after 20 min

Enzyme gradually loses activity by standing in solution in the cold or in the frozen state

-

Stable in presence of non-ionic detergents

-

Stable to freeze-drying

-

Unstable to lyophilization

-

unstable to repeated freezing and thawing

-

0°C, stable for at least 2 weeks

-

-

ammonium sulfate precipitation, MonoS column chromatography, and MonoP column chromatography

-

709715

anion exchange chromatography

P0CY29

682748

anti-FLAG M2 affinity gel filtration

DEAE Sephadex A-25 gel filtration and hydroxyapatite column chromatography

Q5AC08

753796

from the culture medium of a virulent strain

-

MonoS column chromatography

Ni-NTA column chromatography

-

purified from culture supernatant, using ion-exchange chromatography, followed by gel filtration

recombinant

-

-

-

Candida albicans ATCC 10231 and ATCC 10261, contain two genes for a secreted aspartate proteinase, PRA10 and PRA11, cloned and expressed in Escherichia coli TG1 and DH5alpha

-

30686

expressed in Escherichia coli M15 cells

-

expressed in Escherichia coli Top-10 cells

9 entries

expressed in Pichia pastoris

expressed in Pichia pastoris strain GS115

expression in Escherichia coli

-

expression in Pichia pastoris

P0CY29

682748

expression of the Sapp2p precursor in E.coli

P32950

679921

combination of fluconazole with clotrimazole can cause a down-regulation of gene expression of isoforms SAP2 and SAP4

expression of SAPP1 is induced only by the presence of exogenous protein as the sole nitrogen source

for good Sap-inducing conditions, cells are incubated in 1.2% (w/v) yeast carbon base medium supplemented with 0.1% (w/v) bovine serum albumin, pH 5.0, at 37°C for 48 h under slight agitation (100 rpm)

-

707937

isoforms SAP5 and SAP6 mRNA are expressed higher in Candida albicans strain SC5314 than strain VE175